

# End of Study report

<b>I General information</b>	
EudraCT number	2014-003303-30
NL number	NL50440.078.14
<b>Title:</b> <i>Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low molecular-weight heparin: a randomized controlled trial (TropicALL)</i>	
Sponsor	Stichting Kinderoncologie Nederland (SKION)
Participating sites	<input type="checkbox"/> singlecenter:
	<input checked="" type="checkbox"/> multicenter, national
Principal Investigator	Dr. C.H. van Ommen / Dr. M.D. van de Wetering

<b>II Study status</b>	
<input type="checkbox"/> Terminated as planned	End date of study:
<input checked="" type="checkbox"/> Early Termination	End date early termination: 18-DEC-2018
<b>Reason for early termination:</b> <i>After 3.5 years inclusion no subjects included. There are competitive trials in the same population and trials with the same primary endpoint. We do not expect improvement of inclusion rate the next few year and will not reach the inclusion targets.</i>	
<b>How many participants were included at the time it was decided to terminate the study early? What are the consequences for these participants?</b> <i>No participants were included in the study, no consequences for participants.</i>	
<b>What are the consequences of the early termination for the study results?</b> <i>No statistical analysis on these results is feasible. We won't be able to answer the primary and secondary research questions of the study.</i>	

<b>III Status inclusion</b>	
How many participants are included in the study?	0
What is the total number of participants that needed to be included according to protocol?	354
<b>What is the cause for not reaching the intended number of participants?</b> <i>There are competitive trials in the same population and trials with the same primary endpoint.</i>	

<b>IV Report drafted by</b>	
Name and function:	J. Mur, Trialmanager
Date report	04-MAR-2021